The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
about
Trials with 'epigenetic' drugs: an updateHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyHistone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.HDAC expression and activity is upregulated in diseased lupus-prone mice.Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.Brentuximab vedotinFrom empiric to mechanism-based therapy for peripheral T cell lymphoma.Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphomaDesign, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors
P2860
Q27000542-F5894653-28B4-4983-B754-8E5DE66AC273Q28082536-9F413111-720F-4D73-83AC-DBC88CC23B7FQ30431647-04FBC680-9598-47B4-9844-D4E10EEDEA71Q33410761-854D5B9D-21D7-4A24-81E7-5693F903F26AQ34557179-B5619E99-3303-4CF1-AA56-BCA5443A717AQ35223868-FBA931A8-02A3-444B-8AE6-62527267F35BQ35953399-6A39A5C5-1F5A-4A48-9A3D-75B78DC40FEEQ36338516-80D46FA5-AC7C-4BF9-9904-3D0914D08CB3Q36814349-C832EA93-D858-449D-B034-E42AAF541DFDQ37296330-9AB3199E-DF26-4476-9351-F246D8ED8278Q37821337-DEF2A49D-7383-4127-B234-38EC0975C6AFQ37873498-51C8ADA8-8C36-4752-B15D-65156C9E621BQ38017578-9BD02C86-75B6-465C-B11D-82552F2E7B02Q38186617-5B26383C-740F-49B8-8081-32FD8A89A016Q38759986-92A0B1BD-8E7C-4924-B835-A93BE2238AFBQ38976490-7C22D2BA-6A0D-48F0-B388-8D7ADD2F80C0Q43269281-BC401D03-7915-4185-A5D7-CAD7E1168A04Q46697939-2CC07D73-C7F1-4E8C-9240-617E95579498Q48267384-67EEE13C-CB9C-4CC1-89BF-7F69C64350FCQ50861558-58926FE5-7AA1-49BC-B63E-21F74090E230Q52590685-6249AF1C-5402-477B-BB73-99D4E1100577Q57787094-DB581E4F-31CA-4F8B-A646-6A59C054E64BQ58862225-3CDA122C-023B-4804-B899-215500F5EB45
P2860
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@ast
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@en
type
label
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@ast
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@en
prefLabel
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@ast
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@en
P2093
P2860
P1476
The class-I HDAC inhibitor MGC ...... n HDAC6-independent mechanism.
@en
P2093
Anas Younes
Carla Heise
Daniela Buglio
Helen Brady
Jeffrey Besterman
Kyle MacBeth
Noor M Khaskhely
Robert E Martell
Vidya Mamidipudi
P2860
P304
P356
10.1111/J.1365-2141.2010.08342.X
P407
P577
2010-09-29T00:00:00Z